Clinical Case Reports, Volume 14, Issue 11, November 2026.ABSTRACT Hepatic AL amyloidosis can cause severe cholestasis independent of marrow tumor burden. In patients with absolute contraindications to high‐dose steroids—such as steroid‐induced psychosis—tailored daratumumab regimens with low‐dose corticosteroids can drive rapid, life‐saving organ reversal.
R. Ceccarelli +8 more
wiley +1 more source
Contrasting molecular and pharmacodynamic signatures of response and resistance to sequential bortezomib and temozolomide in recurrent IDH-wildtype glioblastoma and grade 4 IDH-mutant astrocytoma: an exploratory interim analysis of NCT03643549 phase IB/II trial [PDF]
Dorota Goplen +10 more
openalex +1 more source
MedComm, Volume 7, Issue 11, November 2026.Cerebral cavernous malformation (CCM) gene complex deficiency dual‐regulates YAP activity via a “dual‐pronged” mechanism: relieving LATS‐mediated inhibition to license YAP nuclear translocation, and promoting MAP3K3‐mediated YAP phosphorylation to stabilize YAP–KLF4 association.
Tingting Ye +11 more
wiley +1 more source
Dihydrolipoamide dehydrogenase (DLD) is a novel molecular target of bortezomib
Cell Death and DiseaseProteasome inhibitors (PIs), such as bortezomib and calfizomib, were backbone agents in the treatment of multiple myeloma (MM). In this study, we investigated bortezomib interactors in MM cells and identified dihydrolipoamide dehydrogenase (DLD) as a ...
Yu Feng +14 more
doaj +1 more source
Covalent drug discovery: Progress against key targets, emerging strategies and lessons learnt
British Journal of Pharmacology, Volume 183, Issue 22, Page 6574-6606, November 2026.Abstract Covalent drug discovery is currently experiencing a boom in industrial and academic interest. To date, at least 75 covalent drugs have received regulatory approval, targeting both traditional target classes and more challenging proteins for which other approaches failed. In many cases, unique aspects of covalent targeting are essential for the
Charles P. Brown +2 more
wiley +1 more source
Targeting protein–protein interactions with reversible covalent modalities: Non‐cysteine chemistries
British Journal of Pharmacology, Volume 183, Issue 22, Page 6607-6626, November 2026.Abstract Protein–protein interactions (PPIs) are central to diverse cellular functions, and represent a rapidly expanding class of therapeutic targets. Advancements in covalent drug design have enabled small‐molecule drugs to overcome challenges associated with engaging these targets, such as limited durations of action and difficult‐to‐drug (expansive,
Ruchira Basu, Steven Fletcher
wiley +1 more source
Stereochemical Control in the Matteson Reaction
Chemistry – A European Journal, Volume 32, Issue 40, 27 October 2026.The Matteson homologation is a highly versatile method for the stereoselective insertion of carbenoids into boronic esters. Through iterative application of the process, complex chiral molecules can be synthesized. The stereoselectivity of the reaction is determined by a chiral diol incorporated in the boronic ester.
Hae Mo Lee, Christoph Hirschhäuser
wiley +1 more source
Retraction Note: Leucovorin Enhances the Anti-cancer Effect of Bortezomib in Colorectal Cancer Cells [PDF]
Shu Wang +7 more
openalex +1 more source
Clinical, electrophysiological, cutaneous sensory, and autonomic changes in patients with multiple myeloma following bortezomib treatment [PDF]
Young Gi Min +5 more
openalex +1 more source